Literature DB >> 6159539

Interferon treatment inhibits glycosylation of a viral protein.

R K Maheshwari, D K Banerjee, C J Waechter, K Olden, R M Friedman.   

Abstract

Earlier, we reported a 30-200-fold reduction in the yield of infectious vesicular stomatitis virus (VSV) released from L cells treated with 10-30 reference units ml-1 of interferon (IFN); however, in these cultures virus particle production, as measured by VSV particle-associated viral RNA, virus nucleocapsid protein and viral transcriptase, was inhibited less than 10-fold. There was biochemical and morphological evidence of a significant reduction in glycoprotein (G) and membrane protein (M) of VSV particles released from IFN-treated cells. We compare here the effects of tunicamycin (TM) and IFN in L cells. Treatment with TM or IFN reduced the production of infectious VSV particles, decreased the amount of G and M proteins in VSV released from treated cells, and inhibited an early step in the formation of asparagine-linked oligosaccharide chains, the incorporation by membrane preparations from treated cells of N-acetylglucosamine into glycolipids with the properties of dolichol derivatives.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159539     DOI: 10.1038/287454a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  10 in total

1.  Cell-type-specific growth restriction of vesicular stomatitis virus polR mutants is linked to defective viral polymerase function.

Authors:  Derek Ostertag; Traci M Hoblitzell-Ostertag; Jacques Perrault
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

2.  Interferon-α alters host glycosylation machinery during treated HIV infection.

Authors:  Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen
Journal:  EBioMedicine       Date:  2020-08-19       Impact factor: 8.143

3.  Accumulation and breakdown of RNA-deficient intracellular virus particles in interferon-treated NIH 3T3 cells chronically producing Moloney murine leukemia virus.

Authors:  M Aboud; Y Hassan
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

4.  Intracellular production of virus particles and viral components in NIH/3T3 cells chronically infected with Moloney murine leukemia virus: effect of interferon.

Authors:  M Aboud; R Kimchi; M Bakhanashvili; S Salzberg
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

5.  Effect of interferon on the replication of mink cell focus-inducing virus in murine cells: synthesis, processing, assembly, and release of viral proteins.

Authors:  J A Bilello; N A Wivel; P M Pitha
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

6.  Effect of interferon on assembly of intracellular Moloney murine leukemia virus particles in chronically infected 3T3/NIH cells.

Authors:  M Aboud; Y Hassan; M Huleihel
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

7.  Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin.

Authors:  P J Rottier; M C Horzinek; B A van der Zeijst
Journal:  J Virol       Date:  1981-11       Impact factor: 5.103

Review 8.  Dendritic spine pathology and thrombospondin-1 deficits in Down syndrome.

Authors:  Maria D Torres; Octavio Garcia; Cindy Tang; Jorge Busciglio
Journal:  Free Radic Biol Med       Date:  2017-09-28       Impact factor: 7.376

9.  Deficient incorporation of spike protein into virions contributes to the lack of infectivity following establishment of a persistent, non-productive infection in oligodendroglial cell culture by murine coronavirus.

Authors:  Yin Liu; Werner Herbst; Jianzhong Cao; Xuming Zhang
Journal:  Virology       Date:  2010-10-28       Impact factor: 3.616

10.  A role for thrombospondin-1 deficits in astrocyte-mediated spine and synaptic pathology in Down's syndrome.

Authors:  Octavio Garcia; Maria Torres; Pablo Helguera; Pinar Coskun; Jorge Busciglio
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.